Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
3.150
-0.010 (-0.32%)
At close: Jun 27, 2025, 4:00 PM
3.200
+0.050 (1.59%)
After-hours: Jun 27, 2025, 7:15 PM EDT
Cardiff Oncology Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Cardiff Oncology stock ranges from a low of $3.50 to a high of $18. The average analyst price target of $10.5 forecasts a 233.33% increase in the stock price over the next year.
Price Target: $10.50 (+233.33%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cardiff Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold Initiates $3.5 | Hold | Initiates | $3.5 | +11.11% | Jun 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $18 | Strong Buy | Maintains | $17 → $18 | +471.43% | May 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $17 | Strong Buy | Maintains | $13 → $17 | +439.68% | Feb 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $7 → $10 | Buy | Maintains | $7 → $10 | +217.46% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +312.70% | Nov 8, 2024 |
Financial Forecast
Revenue This Year
413.54K
from 683.00K
Decreased by -39.45%
Revenue Next Year
291.42K
from 413.54K
Decreased by -29.53%
EPS This Year
-0.83
from -0.95
EPS Next Year
-0.99
from -0.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 735,000 | 630,000 | 420,000 | ||
| Avg | 413,539 | 291,424 | 122,400 | ||
| Low | 98,000 | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.6% | 52.3% | 44.1% | ||
| Avg | -39.5% | -29.5% | -58.0% | ||
| Low | -85.7% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.72 | -0.88 | -1.20 | ||
| Avg | -0.83 | -0.99 | -1.25 | ||
| Low | -0.96 | -1.12 | -1.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.